These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 24452422)

  • 1. Obeticholic acid: a new light in the shadows treating portal hypertension?
    Gracia-Sancho J; Hernández-Gea V; Garcia-Pagán JC
    Hepatology; 2014 Jun; 59(6):2072-3. PubMed ID: 24452422
    [No Abstract]   [Full Text] [Related]  

  • 2. Obeticholic acid, a Farensoid-X receptor agonist, improves portal hypertension by two distinct pathways in cirrhotic rats.
    Mookerjee R; Mehta G; Jalan R
    Hepatology; 2014 Nov; 60(5):1798-9. PubMed ID: 24623154
    [No Abstract]   [Full Text] [Related]  

  • 3. Reply: To PMID 24259407.
    Verbeke L; Trebicka J; Laleman W
    Hepatology; 2014 Nov; 60(5):1799-800. PubMed ID: 24623183
    [No Abstract]   [Full Text] [Related]  

  • 4. Obeticholic acid, a farnesoid X receptor agonist, improves portal hypertension by two distinct pathways in cirrhotic rats.
    Verbeke L; Farre R; Trebicka J; Komuta M; Roskams T; Klein S; Elst IV; Windmolders P; Vanuytsel T; Nevens F; Laleman W
    Hepatology; 2014 Jun; 59(6):2286-98. PubMed ID: 24259407
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The use of obeticholic acid for the management of non-viral liver disease: current clinical practice and future perspectives.
    Gitto S; Guarneri V; Sartini A; Andreone P
    Expert Rev Gastroenterol Hepatol; 2018 Feb; 12(2):165-171. PubMed ID: 29082798
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FXR Agonists: From Bench to Bedside, a Guide for Clinicians.
    Alawad AS; Levy C
    Dig Dis Sci; 2016 Dec; 61(12):3395-3404. PubMed ID: 27734248
    [No Abstract]   [Full Text] [Related]  

  • 7. Obeticholic Acid: First Global Approval.
    Markham A; Keam SJ
    Drugs; 2016 Aug; 76(12):1221-6. PubMed ID: 27406083
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Obeticholic acid: expanding the therapeutic landscape of NASH.
    Arrese M; Cabrera D; Barrera F
    Ann Hepatol; 2015; 14(3):430-2. PubMed ID: 25864227
    [No Abstract]   [Full Text] [Related]  

  • 9. NAFLD: obeticholic acid for the treatment of fatty liver disease--NASH no more?
    Ray K
    Nat Rev Gastroenterol Hepatol; 2015 Jan; 12(1):1. PubMed ID: 25421586
    [No Abstract]   [Full Text] [Related]  

  • 10. New cellular and molecular targets for the treatment of portal hypertension.
    Gracia-Sancho J; Maeso-Díaz R; Fernández-Iglesias A; Navarro-Zornoza M; Bosch J
    Hepatol Int; 2015 Apr; 9(2):183-91. PubMed ID: 25788198
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plecanatide, Nusinersen, and Obeticholic acid.
    Hussar DA; Douglas DK
    J Am Pharm Assoc (2003); 2017; 57(3):416-418. PubMed ID: 28506401
    [No Abstract]   [Full Text] [Related]  

  • 12. Obeticholic acid (Ocaliva) for primary biliary cholangitis.
    Med Lett Drugs Ther; 2017 Mar; 59(1517):53-55. PubMed ID: 28323811
    [No Abstract]   [Full Text] [Related]  

  • 13. Obeticholic acid and resveratrol in nonalcoholic fatty liver disease: all that is gold does not glitter, not all those who wander are lost.
    Musso G
    Hepatology; 2015 Jun; 61(6):2104-6. PubMed ID: 25753820
    [No Abstract]   [Full Text] [Related]  

  • 14. Effect of obeticholic acid on liver regeneration following portal vein embolization in an experimental model.
    Olthof PB; Huisman F; Schaap FG; van Lienden KP; Bennink RJ; van Golen RF; Heger M; Verheij J; Jansen PL; Olde Damink SW; van Gulik TM
    Br J Surg; 2017 Apr; 104(5):590-599. PubMed ID: 28195307
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The response of patients with bile acid diarrhoea to the farnesoid X receptor agonist obeticholic acid.
    Walters JR; Johnston IM; Nolan JD; Vassie C; Pruzanski ME; Shapiro DA
    Aliment Pharmacol Ther; 2015 Jan; 41(1):54-64. PubMed ID: 25329562
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is obeticholic Acid the solution to nonalcoholic steatohepatitis?
    Wong VW; Wong GL; Chan FK
    Gastroenterology; 2015 Apr; 148(4):851-2. PubMed ID: 25726736
    [No Abstract]   [Full Text] [Related]  

  • 17. Trials of obeticholic acid for non-alcoholic steatohepatitis.
    Armstrong MJ; Newsome PN
    Lancet; 2015 Jul; 386(9988):28. PubMed ID: 26169862
    [No Abstract]   [Full Text] [Related]  

  • 18. Trials of obeticholic acid for non-alcoholic steatohepatitis.
    Musso G; Cassader M; Gambino R
    Lancet; 2015 Jul; 386(9988):27. PubMed ID: 26169860
    [No Abstract]   [Full Text] [Related]  

  • 19. Trials of obeticholic acid for non-alcoholic steatohepatitis - Authors' reply.
    Neuschwander-Tetri BA; Van Natta ML; Tonascia J; Brunt EM; Kleiner DE
    Lancet; 2015 Jul; 386(9988):28-29. PubMed ID: 26169861
    [No Abstract]   [Full Text] [Related]  

  • 20. Obeticholic acid for severe bile acid diarrhea with intestinal failure: A case report and review of the literature.
    Hvas CL; Ott P; Paine P; Lal S; Jørgensen SP; Dahlerup JF
    World J Gastroenterol; 2018 Jun; 24(21):2320-2326. PubMed ID: 29881241
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.